Callahan Advisors LLC Acquires 7,297 Shares of Gilead Sciences, Inc. (GILD)

Callahan Advisors LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 90,056 shares of the biopharmaceutical company’s stock after acquiring an additional 7,297 shares during the period. Callahan Advisors LLC’s holdings in Gilead Sciences were worth $7,296,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. FMR LLC grew its holdings in shares of Gilead Sciences by 1.1% in the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after buying an additional 258,005 shares during the period. Seizert Capital Partners LLC grew its holdings in shares of Gilead Sciences by 4.6% in the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after buying an additional 27,547 shares during the period. Investment Centers of America Inc. grew its holdings in shares of Gilead Sciences by 7.2% in the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after buying an additional 1,958 shares during the period. Vanguard Group Inc. grew its holdings in shares of Gilead Sciences by 2.4% in the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after buying an additional 2,148,697 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Gilead Sciences by 0.7% in the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after buying an additional 116,780 shares during the period. Institutional investors own 75.94% of the company’s stock.

A number of brokerages recently weighed in on GILD. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $85.03.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.70 on Wednesday. The firm has a market cap of $94,978.82, a PE ratio of 8.28, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last three months, insiders sold 494,999 shares of company stock worth $37,404,139. Insiders own 1.30% of the company’s stock.

WARNING: “Callahan Advisors LLC Acquires 7,297 Shares of Gilead Sciences, Inc. (GILD)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/27/callahan-advisors-llc-acquires-7297-shares-of-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit